2024-06-07 04:44:14 ET
Summary
- Pfizer is expected to experience growth in cancer treatments due to the rising global incidence of cancer, particularly aggressive forms, in young adults.
- Recent acquisitions, including Seagen and Trillium Therapeutics, have expanded Pfizer's portfolio of cancer treatments.
- Despite weak Q1 financials, Pfizer has increased its earnings forecast, plans to invest in R&D, and has a strong cash position.
- Legal challenges and potential side effects of synthetic uridine in mRNA vaccines pose unquantifiable risks.
Preamble
Just over a year ago I wrote a hit piece on Pfizer Inc. ( PFE ) titled; Don't Bank On mRNA vaccines. I made the case that the company would fail to reach their revenue targets for their mRNA concoctions. In the Q4 2022 report , the company forecast around $10 billion in sales for Comirnaty (Approximately 100 million doses * Circa $100 per dose). Unfortunately for Pfizer investors, the figure given for vaccine revenue for the Q4 2023 period was around half the predicted by the management. As a result, the stock has tanked the lion's share of 30% since publication, however, there are signs of a deceleration in the down trend.
The thesis of this piece is that the company's oncology medications will see a ballooning demand over the years ahead due to the unfortunate rise in the incidence of cancers worldwide....
Read the full article on Seeking Alpha
For further details see:
Pfizer: Surging Cancer Rates Will Boost Revenues